winner
- Merrimack Pharmaceuticals, Inc. MACK Shares rose 212.8% to close at $12.51 on Wednesday after partner Ipsen reported that Onivyde met its primary and key secondary endpoints. Merrimack is eligible for up to $450 million in milestone payments for the treatment of pancreatic cancer.
- Beginning Medical, Inc. Om up 29.9% to close at $14.90 after the company reported better-than-expected Q3 results.
- NeuroBo Pharmaceuticals, Inc. NRBO Shares gained 29.6% to close at $1.62. NeuroBo announced the closing of a $32.3 million underwritten public offering, including full exercise of the over-allotment option and a concurrent private placement.
- Vulnerable Ltd. RSKD up 24.9% to close at $5.11 after the company reported better than expected adjusted EPS and revenue results for the third quarter and raised FY22 revenue guidance.
- Health Catalyst, Inc. HCAT rose 23.3% to $7.98 after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance, which came in above analyst estimates.
- Kala Pharmaceuticals, Inc. KALA Shares rose 22.8% to close at $6.41. On Tuesday, Kala Pharmaceuticals announced that it posted a profit for the third quarter.
- Quotient Technology Inc. QUOTE up 22.8% to close at $3.23 after the company reported a smaller loss in the third quarter.
- OptimizeRx Corporation OPRX up 22.4% to close at $17.77 after better-than-expected Q3 results.
- Vivint Smart Home, Inc. VVNT Soared 20.6% to $8.44 after the company reported upbeat quarterly sales and raised FY22 sales guidance.
- Berkeley Lights Inc. BLI up 20.2% to close at $3.09 after the third quarter results.
- GlycoMimetics, Inc. GLYC up 19.3% to close at $0.8202 after a smaller-than-expected loss in the third quarter.
- LiveRamp Holdings, Inc. RAMP up 17.1% to close at $18.29 after the company reported better-than-expected Q2 results and issued strong guidance.
- Axon Enterprise, Inc. AXON up 14.6% to close at $171.84 after the company reported better-than-expected Q3 results.
- Grow Generation Corp. GRWG…
[ad_2]
Source story